NorthWest EHealth Aligns Business for Commercial Success
News Nov 11, 2016
North West EHealth (NWEH) has become an incorporated company. The limited company’s shareholders are its three current partner organisations, Salford Royal Foundation Trust, Salford Clinical Commissioning Group and the University of Manchester. NWEH was originally established in 2008 as a partnership between these three organisations, in order to develop ground-breaking technology that uses routinely collected healthcare data to improve feasibility and recruitment for clinical trials and support the evaluation of healthcare improvements.
Based in Manchester and Salford Quays, NWEH now has a rapidly growing team of talented software engineers, database analysts, statisticians, researchers and support staff. Changing to a limited company structure is an important development that will allow NWEH to further grow whilst continuing its close collaboration with the NHS and academia.
“Our incorporation gives us greater flexibility to grow our capabilities and to reach a global audience. We look forward to future collaborations and applying our ground-breaking technology, not only to clinical trials, but also to wearable technologies, new diagnostics and other emerging applications worldwide,” said Martin Gibson, Chief Executive, NorthWest EHealth.
“NWEH has been pivotal in the development of clinical trials, not least the Salford Lung Study, the largest ever real-world clinical trial,” said Professor Ian Greer, Vice-President and Dean, Faculty of Biology, Medicine and Health, The University of Manchester. “Trials such as these are made possible by the technology and expertise of the NWEH team, which grew through collaboration with the partner organisations. NWEH is poised, with its incorporation, for much further success and we look forward to continuing a highly successful partnership.”
“NWEH has grown from being an idea to developing the world’s first large-scale, real-world clinical trial. Patients have benefited enormously from this work, and there is still so much more that NWEH can offer with its unique and best in class capabilities,” said Raj Jain, Salford Royal Executive Director lead for NWEH.
"This is a milestone for the CCG. NWEH Limited is already helping the CCG to support improvements in patient care in Salford. We hope that this incorporation will enable further collaborations to enable quicker access to new medicines and better intelligence on healthcare outcomes,” said Anthony Hassall, Chief Operating Officer, Salford Clinical Commissioning Group.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019